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ABSTRACT  
Cardiovascular devices continue to fail due to the lack of non-thrombogenic biomaterials. 
Endothelialized synthetic vascular grafts suffer from difficulties in endothelial cell (EC) 
retention. Tissue engineered vascular constructs that mimic nature are early in their development. 
Vascularization of complex, three-dimensional tissue engineered constructs is critical to their 
function. Central to advancing these strategies is an understanding of EC/blood/biomaterial 
interactions. Cardiovascular disease is the leading cause of death in the United States. Coronary 
artery stent placement has been a significant advance in the percutaneous treatment of 
atherosclerotic disease, but in-stent restenosis remains a fundamental limitation. While animal 
models can provide insight n the pathophysiology of in-stent restenosis, elucidation of the 
relative importance of the various components of the stent and the hemodynamic factors on this 
process and the molecular factors can be difficult. For this purpose, a model system will be 
developed to analyze the relative roles of biomaterial-induced activation of leukocytes on EC 
proliferation and phenotype in the crosstalk between ECs and SMCs in a co-culture system under 
static and dynamic conditions. In previous work, we have demonstrated that biomaterial 
activated leukocytes induce a proinflammatory and procoagulant phenotype on human umbilical 
vein endothelial cells (HUVECs) following static co-culture. Preliminary studies have shown 
that in human aortic EC (HAEC) and human aortic SMC (HASMC) co-culture, HASMC 
phenotype modulates HAEC response to biomaterial-pretreated leukocytes. More specifically, 
the presence of secretory SMCs amplifies the proinflammatory/procoagulant phenotype, while 
the presence of contractile SMCs suppresses this phenotype. The overall hypothesis of this work 
is that biomaterial contact by leukocytes affects downstream healing responses. The specific 
goal of this research is to elucidate the influence of biomaterial-induced activation of leukocytes 
on ECs in an EC/SMC co-culture system. 
In a quiescent native vessel, SMCs are contractile. However, during injury and wound 
healing, they take on a proliferative and secretory phenotype. Thus, it is important to examine 
the impact of both contractile and secretory SMCs on EC interactions with biomaterial-pretreated 
leukocytes to best model vascular healing in vitro. Two co-culture methods were developed to 
obtain more secretory or contractile SMC phenotypes. To characterize the resulting phenotypes, 
ELISAs were performed for secreted interleukin-8 (IL-8) and monocyte chemotactic protein-1 
(MCP-1) and immunohistochemistry for a-smooth muscle actin. Forced contractile HASMCs 
demonstrated organized a-smooth muscle actin filaments, minimal interleukin-8 (IL-8) and 
monocyte chemotactic protein-1 (MCP-1) secretion, and low intracellular cell adhesion 
molecule-1 (ICAM-l), vascular cell adhesion molecule-1 (VCAM-1), and tissue factor 
expression. Organization of a-smooth muscle actin was lost in more secretory HASMCs in co-
culture, and IL-8 and MCP-1 secretion, as well as ICAM-1, VCAM-1, and tissue factor 
expression were significantly upregulated at both time points. Alternately, less secretory 
HASMCs in co-culture showed similar characteristics to forced contractile HASMCs at the 48h 
time point, while by the 72h time point they behaved similarly to more secretory HASMCs. 
These co-culture systems could be useful in better understanding vascular healing, however there 
remain time constraint considerations for maintaining culture integrity/cell phenotype. 
Flow cytometry for proinflammatory and pro/anti-coagulant markers on ECs (in co-
culture with varying concentrations of "secretory" or "contractile" SMCs) following incubation 
with biomaterial-pretreated leukocytes was performed. Proinflammatory markers E-selectin, 
ICAM-1, and VCAM-1 were upregulated on ECs (in co-culture with "secretory" or "contractile" 
SMCs) following incubation with fMLP or biomaterial-pretreated monocytes (but not PMNs) 
above the untreated monocyte control. For all three proinflammatory markers, their expression 
was further increased with increasing number of "secretory" SMCs in co-culture. However, each 
marker showed a different trend when in co-culture with "contractile" SMCs. E-selectin 
expression was suppressed by increasing number of "contractile" SMCs in co-culture, ICAM-1 
expression was not influenced by the presence of "contractile" SMCs, and VCAM-1 expression 
retained the same increasing trend, where increasing number of "contractile" SMCs further 
increased VCAM-1 expression. Procoagulant marker tissue factor was upregulated on ECs (in 
co-culture with varying concentrations of "secretory" or "contractile" SMCs) following 
incubation with fMLP or biomaterial-pretreated monocytes (but not PMNs) above the untreated 
monocyte control. Similar to E-selectin expression, tissue factor expression was further 
increased with increasing number of "secretory" SMCs in co-culture, but alternately suppressed 
by increasing number of "contractile" SMCs in co-culture. Finally, anti-coagulant marker 
thrombomodulin was downregulated on ECs (in co-culture with "secretory" or "contractile" 
SMCs) following incubation with fMLP or biomaterial-pretreated monocytes and PMNs below 
the untreated monocyte or PMN control. This downregulation was suppressed with increasing 
number of both "secretory" and "contractile" SMCs. 
Limitation of EC proliferation in vivo can lead to prolonged endothelial denudation or the 
inability to maintain an EC monolayer on vascular grafts. To examine the proliferative status of 
HAECs in co-culture with more secretory (5% FBS) or less secretory (2% FBS) HASMCs 
following incubation of the HAEC surface with biomaterial-pretreated monocytes or PMNs, the 
same experimental setup was used as described previously for flow cytometry, with the addition 
of BrdU for the final 45 minutes of culture. It was found that treatment of monocultured HAECs 
incubated with TNF-a, as well as fMLP or biomaterial-pretreated monocytes, and not PMNs 
significantly decreased HAEC proliferation in both co-culture systems. In addition, the presence 
of more secretory HASMCs reduced HAEC proliferation for HAECs incubated with media 
alone, untreated monocytes (dose dependent in these cases), or fMLP monocytes, while the 
presence of less secretory HASMCs had no effect on HAEC proliferation. Because the presence 
of more secretory HASMCs significantly reduces HAEC proliferation, further decreases due to 
TNF-a, or fMLP or biomaterial-pretreated monocytes were indiscernible in the co-cultures. 
In the case of endothelial denudation, underlying vascular SMCs interact directly with 
blood cells. To study the effect of biomaterial-pretreated leukocytes directly on HASMC 
phenotype, untreated, fMLP-pretreated, or biomaterial-pretreated monocytes or PMNs were 
applied to more secretory (5% FBS) or forced contractile (serum-free and growth factor-free) 
HASMC monocultures for a 5h or 24h incubations. For more secretory HASMCs (5% FBS), 5h 
treatment with positive controls (TNF-a for pro/anti-coagulant markers, IL-1(3 for 
proinflammatory markers), fMLP-pretreated or biomaterial-pretreated monocytes or PMNs 
significantly upregulated ICAM-1 and tissue factor expression above the untreated control. 
Incubation with fMLP-pretreated monocytes upregulated ICAM-1 and tissue factor expression 
above incubation with untreated monocytes. However, treatment of more secretory HASMCs 
with positive controls, fMLP-pretreated or biomaterial-pretreated leukocytes did not affect 
VCAM-1 or thrombomodulin expression. These trends were maintained at the 24h incubation, 
thus data has been omitted for clarity. For the 5h incubation begun with forced contractile 
HASMCs (serum-free and growth factor-free), treatment with positive controls upregulated 
ICAM-1 and tissue factor expression above the untreated media control. Also, fMLP- or 
biomaterial-pretreated monocytes or PMNs significantly upregulated ICAM-1, tissue factor, and 
VCAM-1 expression above the untreated media control. Furthermore, biomaterial-pretreated 
monocytes significantly upregulated ICAM-1, VCAM-1 and tissue factor expression above 
untreated monocytes. Additionally, fMLP-pretreated monocytes upregulated tissue factor 
expression above untreated monocytes. Lastly, fMLP pretreated PMNs upregulated ICAM-1 
expression above untreated PMNs. For all treatments and markers examined at the 5h time 
point, expression was significantly lower than with more secretory HASMCs. For the 24h time 
point, with forced contractile HASMCs, treatment with positive controls upregulated VCAM-1, 
ICAM-1, and tissue factor expression above the media control. Additionally, fMLP- and 
biomaterial-pretreated monocytes or PMNs, as well as untreated monocytes or PMNs 
significantly upregulated ICAM-1, tissue factor, and VCAM-1 expression above the media 
control. However, fMLP- or biomaterial- pretreated monocytes further upregulated VCAM-1 
and ICAM-1 expression above incubation with untreated monocytes. For the untreated control, 
VCAM-1 expression was significantly higher at the 24h time point as compared to the 5h time 
point. In addition, for all treatments, VCAM-1, ICAM-1, or tissue factor expression was often 
significantly higher at the 24h time point as compared to the 5h time point. 
In these studies we have shown the ability to control the phenotypic state of cultured 
HASMCs based on specific co-culture methods. The presence of "secretory" SMCs in co-
culture enhanced EC activation in response to biomaterial-pretreated monocytes as exemplified 
by increases in E-selectin, ICAM-1, VCAM-1, and tissue factor expression. Alternately, the 
presence of "contractile" SMCs in co-culture suppressed EC activation in response to 
biomaterial-pretreated monocytes (and PMNs to a small degree) as exemplified by subdued E-
selectin, tissue factor, and thrombomodulin expression. Direct incubation of biomaterial-
pretreated monocytes or neutrophils with more secretory HASMCs further increased HASMC 
ICAM-1 and tissue factor expression. Direct incubation of biomaterial-pretreated monocytes or 
neutrophils with forced contractile HASMCs upregulated ICAM-1, VCAM-1, and tissue factor 
expression above the presence of serum-containing media alone. 
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